{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T09:57:37Z","timestamp":1781690257464,"version":"3.54.5"},"reference-count":22,"publisher":"Norwegian Medical Association","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.25.0582","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T22:15:39Z","timestamp":1765836939000},"source":"Crossref","is-referenced-by-count":0,"title":["Myasthenia gravis \u2013 new, improved treatment"],"prefix":"10.4045","volume":"145","author":[{"given":"Nils Erik","family":"Gilhus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina Hatl\u00f8","family":"Maniaol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Gilhus\u00a0NE. Myasthenia Gravis. N Engl J Med 2016; 375: 2570\u201381. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28029925&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMra1602678","DOI":"10.1056\/NEJMra1602678"},{"key":"ref=2","unstructured":"Gilhus\u00a0NE, Tzartos\u00a0S, Evoli\u00a0A et al. Myasthenia gravis. Nat Rev Dis Primers 2019; 5: 30. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31048702&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038%2Fs41572-019-0079-y"},{"key":"ref=3","unstructured":"Gilhus\u00a0NE, Breiner\u00a0A. Epidemiology of myasthenia gravis. Int Rev Neurobiol 2025; 182: 161\u201396. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=40675734&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fbs.irn.2025.04.028"},{"key":"ref=4","unstructured":"Gilhus\u00a0NE, Andersen\u00a0H, Andersen\u00a0LK et al. Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment. Eur J Neurol 2024; 31: e16229. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38321574&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111%2Fene.16229"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Gilhus\u00a0NE, Verschuuren\u00a0JJGM, Hovland\u00a0SIB et al. Myasthenia gravis: do not forget the patient perspective. Neuromuscul Disord 2021; 31: 1287\u201395. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=34635387&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.nmd.2021.07.396","DOI":"10.1016\/j.nmd.2021.07.396"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Gilhus\u00a0NE, Kerty\u00a0E, L\u00f8seth\u00a0S et al. Myasthenia gravis - diagnostikk og behandling. Tidsskr Nor Legeforen 2016; 136: 1089\u201394. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=27381787&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.4045%2Ftidsskr.15.1259","DOI":"10.4045\/tidsskr.15.1259"},{"key":"ref=7","unstructured":"Howard\u00a0JF, Utsugisawa\u00a0K, Benatar\u00a0M et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 2017; 16: 976\u201386. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29066163&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS1474-4422(17)30369-1"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Meisel\u00a0A, Annane\u00a0D, Vu\u00a0T et al. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase\u00a03 CHAMPION MG open-label extension. J Neurol 2023; 270: 3862\u201375. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=37103755&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs00415-023-11699-x","DOI":"10.1007\/s00415-023-11699-x"},{"key":"ref=9","unstructured":"Howard\u00a0JF, Bresch\u00a0S, Genge\u00a0A et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol 2023; 22: 395\u2013406. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=37059508&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS1474-4422(23)00080-7"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Clifford\u00a0KM, Hobson-Webb\u00a0LD, Benatar\u00a0M et al. Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis. Muscle Nerve 2019; 59: 404\u201310. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=30575980&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002%2Fmus.26404","DOI":"10.1002\/mus.26404"},{"key":"ref=11","unstructured":"Bril\u00a0V, Dru\u017cd\u017c\u00a0A, Grosskreutz\u00a0J et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol 2023; 22: 383\u201394. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=37059507&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS1474-4422(23)00077-7"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Antozzi\u00a0C, Guptill\u00a0J, Bril\u00a0V et al. Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis: Results From the Randomized Phase 2 Vivacity-MG Study. Neurology 2024; 102: e207937. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38165333&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1212%2FWNL.0000000000207937","DOI":"10.1212\/WNL.0000000000207937"},{"key":"ref=13","unstructured":"Yan\u00a0C, Yue\u00a0Y, Guan\u00a0Y et al. Batoclimab vs Placebo for Generalized Myasthenia Gravis: A Randomized Clinical Trial. JAMA Neurol 2024; 81: 336\u201345. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38436998&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001%2Fjamaneurol.2024.0044"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Lindroos\u00a0JLV, Bj\u00f8rk\u00a0MH, Gilhus\u00a0NE. Transient Neonatal Myasthenia Gravis as a Common Complication of a Rare Disease: A Systematic Review. J Clin Med 2024; 13: 1136. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38398450&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.3390%2Fjcm13041136","DOI":"10.3390\/jcm13041136"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Zhao\u00a0C, Pu\u00a0M, Chen\u00a0D et al. Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis. Front Neurol 2021; 12: 736190. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=34721267&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.3389%2Ffneur.2021.736190","DOI":"10.3389\/fneur.2021.736190"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Nowak\u00a0RJ, Coffey\u00a0CS, Goldstein\u00a0JM et al. Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study. Neurology 2022; 98: e376\u201389. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=34857535&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1212%2FWNL.0000000000013121","DOI":"10.1212\/WNL.0000000000013121"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Piehl\u00a0F, Eriksson-Dufva\u00a0A, Budzianowska\u00a0A et al. Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial. JAMA Neurol 2022; 79: 1105\u201312. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=36121672&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001%2Fjamaneurol.2022.2887","DOI":"10.1001\/jamaneurol.2022.2887"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Nowak\u00a0RJ, Benatar\u00a0M, Ciafaloni\u00a0E et al. A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis. N Engl J Med 2025; 392: 2309\u201320. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=40202593&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056%2FNEJMoa2501561","DOI":"10.1056\/NEJMoa2501561"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Rejdak\u00a0K, Szklener\u00a0S, Korchut\u00a0A et al. Cladribine in myasthenia gravis: a pilot open-label study. Eur J Neurol 2020; 27: 586\u20139. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=31705552&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111%2Fene.14124","DOI":"10.1111\/ene.14124"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Nie\u00a0W, Yang\u00a0X, Ma\u00a0M et al. Chimeric antigen receptor T cell therapy for autoimmune diseases. Curr Opin Immunol 2025; 95: 102596. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=40561659&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.coi.2025.102596","DOI":"10.1016\/j.coi.2025.102596"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Skov\u00a0M, Ruijs\u00a0TQ, Gr\u00f8nneb\u00e6k\u00a0TS et al. The ClC-1 chloride channel inhibitor NMD670 improves skeletal muscle function in rat models and patients with myasthenia gravis. Sci Transl Med 2024; 16: eadk9109. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38507469&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1126%2Fscitranslmed.adk9109","DOI":"10.1126\/scitranslmed.adk9109"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Engebretsen\u00a0I, Gilhus\u00a0NE, Kristiansen\u00a0IS et al. The epidemiology and societal costs of myasthenia gravis in\u00a0Norway: A non-interventional study using national registry\u00a0data. Eur J Neurol 2024; 31: e16233. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38323756&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111%2Fene.16233","DOI":"10.1111\/ene.16233"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":["Myasthenia gravis \u2013 ny og bedre behandling"],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T09:39:36Z","timestamp":1781689176000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2025\/12\/kronikk\/myasthenia-gravis-ny-og-bedre-behandling"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":22,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,12,16]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.25.0582","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]}}}